- Home
- BCDA vs AMST Comparison
BCDA vs AMST Comparison
Compare BCDA & AMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- AMST
- Stock Information
- Founded
- BCDA N/A
- AMST 2017
- Country
- BCDA United States
- AMST United States
- Employees
- BCDA N/A
- AMST N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- AMST Computer Software: Prepackaged Software
- Sector
- BCDA Health Care
- AMST Technology
- Exchange
- BCDA Nasdaq
- AMST Nasdaq
- Market Cap
- BCDA 7.9M
- AMST 6.6M
- IPO Year
- BCDA N/A
- AMST 2020
- Fundamental
- Price
- BCDA $2.68
- AMST $2.62
- Analyst Decision
- BCDA Strong Buy
- AMST
- Analyst Count
- BCDA 1
- AMST 0
- Target Price
- BCDA $25.00
- AMST N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- AMST 15.3K
- Earning Date
- BCDA 11-06-2024
- AMST 11-11-2024
- Dividend Yield
- BCDA N/A
- AMST N/A
- EPS Growth
- BCDA N/A
- AMST N/A
- EPS
- BCDA N/A
- AMST N/A
- Revenue
- BCDA $428,000.00
- AMST $166,881.00
- Revenue This Year
- BCDA $6.92
- AMST N/A
- Revenue Next Year
- BCDA N/A
- AMST N/A
- P/E Ratio
- BCDA N/A
- AMST N/A
- Revenue Growth
- BCDA 0.71
- AMST N/A
- 52 Week Low
- BCDA $1.96
- AMST $1.72
- 52 Week High
- BCDA $23.25
- AMST $4.34
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- AMST 58.51
- Support Level
- BCDA $2.39
- AMST $2.36
- Resistance Level
- BCDA $2.90
- AMST $2.64
- Average True Range (ATR)
- BCDA 0.18
- AMST 0.13
- MACD
- BCDA -0.00
- AMST 0.02
- Stochastic Oscillator
- BCDA 53.70
- AMST 78.82
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology-driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are businesses, universities and colleges, and K-12 schools.